Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Trialsnnc0519-0130novo nordisktype 2 diabetesphase 2

Novo completes phase 2 dose-finding study of weekly NNC0519-0130

The 40-week trial tested up to seven once-weekly subcutaneous doses against blood sugar and body weight in type 2 diabetes.

PR
By Priya Raman · Science Reporter
Sep 21 08:00 ETSource: ClinicalTrials.gov

The wire

  1. 01ClinicalTrials.gov lists NCT06326047, a phase 2 randomised dose-finding study of once-weekly NNC0519-0130 in type 2 diabetes, started 18 March 2024, as completed.
  2. 02Participants took one to three weekly subcutaneous injections over roughly 40 weeks, with glucose lowering and body weight as the stated focus.
  3. 03No results are posted; sponsor Novo Nordisk has not disclosed efficacy or safety data, and the compound's class and mechanism are not described in the registry entry.

From the source

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

NCT06326047 · PHASE2 · COMPLETED · Sponsor: Novo Nordisk A/S · Conditions: Diabetes Mellitus, Type 2.

Read at clinicaltrials.gov
Source URL https://clinicaltrials.gov/study/NCT06326047